Eduardo [Analyst]'s questions to Regenxbio Inc (RGNX) leadership • Q1 2025
Question
Speaking for Yi Chen, Eduardo from H.C. Wainwright & Co. inquired about the potential impact of recent government announcements on branded drug pricing on the company's ability to price its gene therapies.
Answer
President and CEO Curran Simpson responded that it is too early to determine the full impact but noted that commentary from industry groups suggests cell and gene therapies may be less affected than broader branded drugs. He stated there is no immediate impact on their plans but it is a macro environmental factor they are monitoring.